NASDAQ:IPCI - IntelliPharmaCeutics Intl Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.4799 -0.02 (-4.00 %)
(As of 11/16/2018 02:09 AM ET)
Previous Close$0.5001
Today's Range$0.4601 - $0.4998
52-Week Range$0.46 - $10.50
Volume215,798 shs
Average Volume107,709 shs
Market Capitalization$2.18 million
P/E Ratio-0.17
Dividend YieldN/A
Beta2.27
IntelliPharmaCeutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Receive IPCI News and Ratings via Email

Sign-up to receive the latest news and ratings for IPCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IPCI
Previous Symbol
CUSIPN/A
Phone416-798-3001

Debt

Debt-to-Equity RatioN/A
Current Ratio0.22
Quick Ratio0.20

Price-To-Earnings

Trailing P/E Ratio-0.17
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.51 million
Price / Sales0.38
Cash FlowN/A
Price / CashN/A
Book Value$0.12 per share
Price / Book4.00

Profitability

EPS (Most Recent Fiscal Year)($2.90)
Net Income$-8,850,000.00
Net Margins-519.58%
Return on EquityN/A
Return on Assets-198.96%

Miscellaneous

Employees62
Outstanding Shares4,350,000
Market Cap$2.18 million
OptionableOptionable

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Frequently Asked Questions

What is IntelliPharmaCeutics Intl's stock symbol?

IntelliPharmaCeutics Intl trades on the NASDAQ under the ticker symbol "IPCI."

When did IntelliPharmaCeutics Intl's stock split? How did IntelliPharmaCeutics Intl's stock split work?

IntelliPharmaCeutics Intl's stock reverse split on Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of IntelliPharmaCeutics Intl stock prior to the reverse split would have 10 shares after the split.

How were IntelliPharmaCeutics Intl's earnings last quarter?

IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) issued its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.70). The company had revenue of $0.58 million for the quarter, compared to analysts' expectations of $0.90 million. View IntelliPharmaCeutics Intl's Earnings History.

When is IntelliPharmaCeutics Intl's next earnings date?

IntelliPharmaCeutics Intl is scheduled to release their next quarterly earnings announcement on Tuesday, November 20th 2018. View Earnings Estimates for IntelliPharmaCeutics Intl.

What price target have analysts set for IPCI?

2 brokerages have issued 12 month target prices for IntelliPharmaCeutics Intl's shares. Their forecasts range from $30.00 to $80.00. On average, they anticipate IntelliPharmaCeutics Intl's share price to reach $55.00 in the next year. This suggests a possible upside of 11,360.7% from the stock's current price. View Analyst Price Targets for IntelliPharmaCeutics Intl.

What is the consensus analysts' recommendation for IntelliPharmaCeutics Intl?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelliPharmaCeutics Intl in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelliPharmaCeutics Intl.

What are Wall Street analysts saying about IntelliPharmaCeutics Intl stock?

Here are some recent quotes from research analysts about IntelliPharmaCeutics Intl stock:
  • 1. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (9/4/2018)
  • 2. Maxim Group analysts commented, "1Q18 revenues were $0.3M, down from $1.1M in 4Q17 (Nov. YE). The decline owes largely to declining generic Focalin sales, citing pricing pressures in the US generics market. IPCI recently raised $4.5M through an equity financing, which extends the runway into 3Q18. However, we believe that over time the generics business for IPCI will continue to grow and provide revenue that helps offset cash burn associated with key programs: Abuse deterrent Oxycodone and PODRAS (preventing overdose); we view both programs as the long-term drivers of the company." (4/18/2018)

Has IntelliPharmaCeutics Intl been receiving favorable news coverage?

News headlines about IPCI stock have been trending somewhat positive on Friday, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IntelliPharmaCeutics Intl earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.

Are investors shorting IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 492,498 shares, a drop of 43.1% from the October 15th total of 865,372 shares. Based on an average daily trading volume, of 414,374 shares, the days-to-cover ratio is currently 1.2 days. Approximately 16.1% of the shares of the company are sold short. View IntelliPharmaCeutics Intl's Current Options Chain.

Who are some of IntelliPharmaCeutics Intl's key competitors?

Who are IntelliPharmaCeutics Intl's key executives?

IntelliPharmaCeutics Intl's management team includes the folowing people:
  • Dr. Isa Odidi, Co-Founder, Chairman, CEO & Co-Chief Scientific Officer (Age 60)
  • Dr. Amina Odidi, Pres, COO, Co-Chief Scientist Officer & Director (Age 58)
  • Mr. Andrew P. Patient B.Acc, C.A., Chief Financial Officer (Age 47)
  • Dr. Patrick N. Yat, Vice-Pres of Chemistry & Analytical Services (Age 60)
  • Mr. Christian Akyempon, VP of Commercial Operations

How do I buy shares of IntelliPharmaCeutics Intl?

Shares of IPCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IntelliPharmaCeutics Intl's stock price today?

One share of IPCI stock can currently be purchased for approximately $0.4799.

How big of a company is IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl has a market capitalization of $2.18 million and generates $5.51 million in revenue each year. The company earns $-8,850,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. IntelliPharmaCeutics Intl employs 62 workers across the globe.

What is IntelliPharmaCeutics Intl's official website?

The official website for IntelliPharmaCeutics Intl is http://www.intellipharmaceutics.com.

How can I contact IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]


MarketBeat Community Rating for IntelliPharmaCeutics Intl (NASDAQ IPCI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe IPCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel